title: Pharmacotherapeutic approach to the treatment of addiction: persistent challenges.
abstract: The sequence of pathophysiological responses to repeated self-administration of addictive compounds is briefly described, as are prospects for development of drugs for addiction and some of those currently available. It is noted that the varying vulnerability of individuals to addictions creates ethical concerns regarding the application of drug abuse pharmacotherapies as they become more efficacious. It is noted further that relapse remains the most persistent challenge in the treatment of addictions.
authors.affiliation: Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, USA. zahmds@slu.edu
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Zahm
mesh_terms: D000427:Alcohol Deterrents / Q000627:therapeutic use; D016739:Behavior, Addictive / Q000188:drug therapy; D018682:GABA Agents / Q000627:therapeutic use; D006801:Humans; D009292:Narcotic Antagonists / Q000627:therapeutic use; D055502:Secondary Prevention; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000517:prevention & control / Q000523:psychology
chemical_list: D000427:Alcohol Deterrents; D018682:GABA Agents; D009292:Narcotic Antagonists
references.citation: Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3125-35
references.pmid: 18640910
references.citation: Nat Neurosci. 2005 Nov;8(11):1442-4
references.pmid: 16251985
references.citation: Synapse. 1991 Sep;9(1):60-5
references.pmid: 1796352
references.citation: NIDA Res Monogr. 1988;84:25-43
references.pmid: 3147384
references.citation: Pharmacol Ther. 2005 Oct;108(1):94-108
references.pmid: 16083966
references.citation: Pharmacol Rep. 2008 Nov-Dec;60(6):755-70
references.pmid: 19211967
references.citation: Nature. 2008 Jul 3;454(7200):118-21
references.pmid: 18500330
references.citation: Br J Pharmacol. 2008 May;154(2):343-57
references.pmid: 18414383
references.citation: Nat Neurosci. 2005 Nov;8(11):1481-9
references.pmid: 16251991
references.citation: Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3147-58
references.pmid: 18640921
references.citation: Pharmacol Ther. 2005 Oct;108(1):3-17
references.pmid: 16098597
references.citation: Am J Psychiatry. 2005 Aug;162(8):1403-13
references.pmid: 16055761
references.citation: Psychopharmacology (Berl). 2009 Oct;206(3):367-76
references.pmid: 19639303
references.citation: Psychopharmacology (Berl). 2003 Jul;168(1-2):3-20
references.pmid: 12402102
references.citation: Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
references.pmid: 2899326
references.citation: Nature. 1999 Sep 16;401(6750):272-6
references.pmid: 10499584
references.citation: Brain Res Brain Res Rev. 1991 Sep-Dec;16(3):223-44
references.pmid: 1665095
references.citation: Neuropsychopharmacology. 2010 Jan;35(1):217-38
references.pmid: 19710631
references.citation: Nat Rev Neurosci. 2009 Aug;10(8):561-72
references.pmid: 19571793
references.citation: Nature. 2001 Jul 12;412(6843):141-2
references.pmid: 11449260
references.citation: Nature. 1997 Apr 24;386(6627):827-30
references.pmid: 9126740
references.citation: Br J Pharmacol. 2008 May;154(2):384-96
references.pmid: 18414400
references.citation: Am J Psychiatry. 1999 Jan;156(1):11-8
references.pmid: 9892292
references.citation: Curr Drug Abuse Rev. 2008 Nov;1(3):303-27
references.pmid: 19430578
references.citation: Pharmacol Ther. 2009 Nov;124(2):235-47
references.pmid: 19683019
references.citation: Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
references.pmid: 8401595
references.citation: Nature. 1997 Apr 24;386(6627):830-3
references.pmid: 9126741
references.citation: Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1976-81
references.pmid: 11172061
references.citation: Neuron. 2005 Sep 15;47(6):795-801
references.pmid: 16157275